Riluzole, disease stage and survival in ALS
نویسندگان
چکیده
منابع مشابه
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
BACKGROUND Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial. A key question is whether the survival benefit occurs at an early stage of disease, late stage, or is spread throughout the course of the disease. To address this question, we used the King's clinical sta...
متن کاملRiluzole and Prognostic Factors in Amyotrophic Lateral Sclerosis Long-term and Short-term Survival: A Population-Based Study of 1149 Cases in Taiwan
BACKGROUND Amyotrophic lateral sclerosis (ALS) is a rare disease in Taiwan; thus, estimation of ALS mortality is difficult. We evaluated factors associated with ALS survival in Taiwan. METHODS The study enrolled 1149 Taiwanese with a primary diagnosis of ALS during 1999-2008. Follow-up information was available for all patients; mean (SD) duration of follow-up was 2.91 (2.62) years. Medical i...
متن کاملInhibiting drug efflux transporters improves efficacy of ALS therapeutics
OBJECTIVE Research identified promising therapeutics in cell models of Amyotrophic Lateral Sclerosis (ALS), but there is limited progress translating effective treatments to animal models and patients, and ALS remains a disease with no effective treatment. One explanation stems from an acquired pharmacoresistance driven by the drug efflux transporters P-glycoprotein (P-gp) and breast cancer-res...
متن کاملCurrent and emerging treatments for amyotrophic lateral sclerosis
BACKGROUND Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative disorder of both upper and lower motoneurons. Currently, the management of ALS is essentially symptoms-based, and riluzole, an antiglutamatergic agent, is the only drug for the treatment of ALS approved by the food and drug administration. OBJECTIVE We reviewed current literature concerning emerging treatmen...
متن کاملA clinical specification for a randomized clinical trial on lithium in amyotrophic lateral sclerosis.
We read with great interest the paper by Fornai et al. (1) on delayed progression of amyotrophic lateral sclerosis (ALS) with lithium. In this study the results of a small randomized clinical trial were also reported. Sixteen patients (4 of whom had the bulbar form of ALS) were randomly selected to receive riluzole plus lithium, and 28 (7 of whom had the bulbar form of ALS) received riluzole on...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Lancet. Neurology
دوره شماره
صفحات -
تاریخ انتشار 2018